These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12379092)

  • 1. Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment.
    Ann Intern Med; 2002 Oct; 137(8):I48. PubMed ID: 12379092
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.
    Bernard L; Vuagnat A; Peytavin G; Hallouin MC; Bouhour D; Nguyen TH; Vildé JL; Bricaire F; Raguin G; de Truchis P; Ghez D; Duong M; Perronne C
    Ann Intern Med; 2002 Oct; 137(8):656-9. PubMed ID: 12379065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hair it is: the long and short of monitoring antiretroviral treatment.
    Gandhi M; Greenblatt RM
    Ann Intern Med; 2002 Oct; 137(8):696-7. PubMed ID: 12379072
    [No Abstract]   [Full Text] [Related]  

  • 4. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.
    Servais J; Peytavin G; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    AIDS; 2001 May; 15(7):941-3. PubMed ID: 11399971
    [No Abstract]   [Full Text] [Related]  

  • 5. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.
    Duval X; Peytavin G; Breton G; Ecobichon JL; Descamps D; Thabut G; Leport C
    AIDS; 2007 Jan; 21(1):106-8. PubMed ID: 17148976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
    Stürmer M; Staszewski S; Doerr HW; Hertogs K
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):967-8. PubMed ID: 14678603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen.
    Liuzzi G; Chirianni A; Clementi M; Zaccarelli M; Antinori A; Piazza M
    AIDS; 2002 Feb; 16(3):503-4. PubMed ID: 11834971
    [No Abstract]   [Full Text] [Related]  

  • 8. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy.
    Bernard L; Peytavin G; Vuagnat A; de Truchis P; Perronne C
    Lancet; 1998 Nov; 352(9142):1757-8. PubMed ID: 9848361
    [No Abstract]   [Full Text] [Related]  

  • 10. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.
    González de Requena D; Gallego O; de Mendoza C; Corral A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2003 Jun; 19(6):457-9. PubMed ID: 12882654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in durability of treatment with initial PI-based regimens.
    Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
    HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of indinavir in HIV-positive pregnant women.
    Hayashi S; Beckerman K; Homma M; Kosel BW; Aweeka FT
    AIDS; 2000 May; 14(8):1061-2. PubMed ID: 10853990
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
    Mueller BU; Sleasman J; Nelson RP; Smith S; Deutsch PJ; Ju W; Steinberg SM; Balis FM; Jarosinski PF; Brouwers P; Mistry G; Winchell G; Zwerski S; Sei S; Wood LV; Zeichner S; Pizzo PA
    Pediatrics; 1998 Jul; 102(1 Pt 1):101-9. PubMed ID: 9651421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
    Harris M; Durakovic C; Rae S; Raboud J; Fransen S; Shillington A; Conway B; Montaner JS
    J Infect Dis; 1998 Jun; 177(6):1514-20. PubMed ID: 9607828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
    Urban AW; Bean P; Aziz D; Graziano FM; Neudeck BL
    Int J STD AIDS; 2003 Feb; 14(2):103-8. PubMed ID: 12662388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.
    Sangeda RZ; Theys K; Beheydt G; Rhee SY; Deforche K; Vercauteren J; Libin P; Imbrechts S; Grossman Z; Camacho RJ; Van Laethem K; Pironti A; Zazzi M; Sönnerborg A; Incardona F; De Luca A; Torti C; Ruiz L; Van de Vijver DA; Shafer RW; Bruzzone B; Van Wijngaerden E; Vandamme AM;
    Infect Genet Evol; 2013 Oct; 19():349-60. PubMed ID: 23523594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 19. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.
    Drusano GL; Bilello JA; Stein DS; Nessly M; Meibohm A; Emini EA; Deutsch P; Condra J; Chodakewitz J; Holder DJ
    J Infect Dis; 1998 Aug; 178(2):360-7. PubMed ID: 9697715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.